Contact
Please use this form to send email to PR contact of this press release:
NovelMed’s Phase II Data in Paroxysmal Nocturnal Hemoglobinuria (PNH) Patients: Ruxoprubart Shows Best-in-Class Efficacy as Monotherapy
TO: